MedNet.nl: Patients treated with icosapent-ethyl in the REDUCE-IT trial had 38% fewer major adverse cardiovascular events than those receiving mixed polyunsaturated omega 3 fatty acids.
11-04-2024 | Cardiac Emergency | News
11-04-2024 | Cardiac Emergency | News
MedNet.nl: Patients treated with icosapent-ethyl in the REDUCE-IT trial had 38% fewer major adverse cardiovascular events than those receiving mixed polyunsaturated omega 3 fatty acids.